Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 18/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033850 | 0.87 | EIF2AK4 (0.54) | EIF2AK4 | |
| SCHEMBL12614086 | 0.84 | EIF2AK4 (0.51) | EIF2AK4 | |
| SCHEMBL1994215 | 0.84 | EIF2AK4 (0.51) | EIF2AK4 | |
| SCHEMBL1997369 | 0.80 | IRAK4 (0.46) | EIF2AK4GPR119 | |
| SCHEMBL1995331 | 0.80 | IRAK4 (0.46) | EIF2AK4GPR119 | |
| SCHEMBL1994794 | 0.80 | IRAK4 (0.46) | EIF2AK4GPR119 | |
| SCHEMBL1996069 | 0.78 | EIF2AK4 (0.45) | EIF2AK4GPR119 | |
| SCHEMBL1995218 | 0.78 | EIF2AK4 (0.47) | EIF2AK4 | |
| SCHEMBL1995220 | 0.78 | EIF2AK4 (0.47) | EIF2AK4 | |
| SCHEMBL1993300 | 0.77 | EIF2AK4 (0.55) | EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | EIF2AK4 211/4885GPR119 1868/4885CKS1B 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.